Head-To-Head Comparison: Moderna (NASDAQ:MRNA) and BioCardia (NASDAQ:BCDA)

Moderna (NASDAQ:MRNA) and BioCardia (NASDAQ:BCDA) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, risk, analyst recommendations, valuation and institutional ownership.

Profitability

This table compares Moderna and BioCardia’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Moderna	-110.04%	-28.74%	-21.83%
BioCardia	-1,999.77%	N/A	-208.38%

Analyst Recommendations

This is a breakdown of current ratings and price targets for Moderna and BioCardia, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	4	16	3	1	2.04
BioCardia	0	0	1	1	3.50

Moderna currently has a consensus price target of $59.60, suggesting a potential upside of 72.15%. BioCardia has a consensus price target of $25.00, suggesting a potential upside of 861.54%. Given BioCardia’s stronger consensus rating and higher probable upside, analysts plainly believe BioCardia is more favorable than Moderna.

Earnings and Valuation

This table compares Moderna and BioCardia”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$3.20 billion	4.18	-$3.56 billion	($9.28)	-3.73
BioCardia	$71,000.00	167.86	-$11.57 million	($4.19)	-0.62

BioCardia has lower revenue, but higher earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Moderna has a beta of 1.86, indicating that its share price is 86% more volatile than the S&P 500. Comparatively, BioCardia has a beta of 1.28, indicating that its share price is 28% more volatile than the S&P 500.

Institutional & Insider Ownership

75.3% of Moderna shares are held by institutional investors. Comparatively, 20.6% of BioCardia shares are held by institutional investors. 15.7% of Moderna shares are held by company insiders. Comparatively, 20.0% of BioCardia shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

BioCardia beats Moderna on 8 of the 14 factors compared between the two stocks.

About Moderna

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

About BioCardia

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.